Pharmaceutical glass manufacturer Stevanato will receive up to $95 million to expand its vials production in the United States.
The company’s subsidiary, OMPI of America, has entered into an agreement to support the Biomedical Advanced Research and Development Authority (BARDA) under the American Rescue Plan Act of 2021.
Stevanato has agreed to expand its planned manufacturing capacity in Fishers, Indiana for both standard and EZ-Fill vials.
In addition, it will provide priority access to designated BARDA vaccine and drug development partners, when necessary.
Franco Moro, CEO of Stevanato, said: “We are honoured to have been selected by BARDA for this important investment which we believe will help fortify the US pharmaceutical supply chain to meet the demands for current and future public health emergencies.
"We believe this investment will rapidly accelerate and scale Stevanato group’s capacity in Indiana and further expand our growth in this key strategic market.”
BARDA provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies and diagnostic tools for public health medical emergencies.
